Jean Bourhis, MD, PhD

home / authors / jean-bourhis-md-phd

Articles

Dr. Bourhis on the OS Benefit of Xevinapant Plus Chemoradiotherapy in HNSCC

October 28th 2022

Jean Bourhis, MD, PhD, discusses the overall survival benefit of xevinapant plus chemoradiotherapy in head and neck squamous cell carcinoma.

Dr. Bourhis on the Rationale to Explore Debio 1143 in Head and Neck Cancer

October 17th 2019

Jean Bourhis, MD, PhD, Radiation Oncology, Centre Hospitalier Universitaire Vaudois, discusses the rationale to explore Debio 1143 in patients with head and neck cancer.

Dr. Bourhis on Results of the Phase II Trial With Debio 1143 in Head and Neck Cancer

October 10th 2019

Jean Bourhis, MD, PhD, Radiation Oncology, Centre Hospitalier Universitaire Vaudois, discusses the results of a phase II trial evaluating the addition of Debio 1143 to concurrent high-dose cisplatin and chemoradiation in high-risk patients with locally advanced squamous cell carcinoma of the head and neck.